KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Asset Writedowns and Impairment (2022 - 2025)

Nektar Therapeutics has reported Asset Writedowns and Impairment over the past 5 years, most recently at $4.4 million for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $4.4 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $4.4 million (down 46.68% YoY), and the annual figure for FY2025 was $4.4 million, down 46.68%.
  • Asset Writedowns and Impairment for Q4 2025 was $4.4 million at Nektar Therapeutics, down from $8.3 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for NKTR hit a ceiling of $57.3 million in Q2 2022 and a floor of -$1.3 million in Q4 2023.
  • Median Asset Writedowns and Impairment over the past 4 years was $7.2 million (2022), compared with a mean of $11.7 million.
  • Peak annual rise in Asset Writedowns and Impairment hit 747.75% in 2023, while the deepest fall reached 117.96% in 2023.
  • Nektar Therapeutics' Asset Writedowns and Impairment stood at $7.2 million in 2022, then crashed by 117.96% to -$1.3 million in 2023, then soared by 740.69% to $8.3 million in 2024, then crashed by 46.68% to $4.4 million in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $4.4 million (Q4 2025), $8.3 million (Q2 2024), and -$1.3 million (Q4 2023) per Business Quant data.